No Data
Esperion Announces New Drug Submissions in Canada for NEXLETOL (Bempedoic Acid) and NEXLIZET (Bempedoic Acid and Ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
Express News | Esperion Therapeutics Inc - No Serious Adverse Events Observed in Bempedoic Acid Trial
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who...
Youngman : Guys I think we're going to be rich someday